{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:11:46Z","timestamp":1789431106250,"version":"build-2803163510"},"reference-count":61,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jtct.2025.06.004","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T14:08:13Z","timestamp":1750255693000},"page":"806.e1-806.e19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Long-Term Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed\/Refractory B-Cell Non-Hodgkin Lymphoma: An Italian Multicenter Collaborative Study"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1473-6046","authenticated-orcid":false,"given":"Corrado","family":"Tarella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Sammassimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4265-2627","authenticated-orcid":false,"given":"Samuele","family":"Frassoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alida","family":"Dominietto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3638-0650","authenticated-orcid":false,"given":"Raffaella","family":"Cerretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Caterina","family":"Mic\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocco","family":"Pastano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1077-5937","authenticated-orcid":false,"given":"Martina","family":"Pennisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara Di","family":"Chio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Ghiggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gottardo","family":"De Angelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Algarotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1355-1587","authenticated-orcid":false,"given":"Patrizia","family":"Chiusolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Derenzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Sica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Corradini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Bagnardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6512-6080","authenticated-orcid":false,"given":"Emanuele","family":"Angelucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3739-7502","authenticated-orcid":false,"given":"Alessandro","family":"Rambaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2680-0984","authenticated-orcid":false,"given":"William G","family":"Arcese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Dodero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Bacigalupo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2025.06.004_bib0001","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/sj.bmt.1703535","article-title":"Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe","volume":"29","author":"Urbano-Ispizua","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.06.004_bib0002","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1016\/j.ejca.2007.08.020","article-title":"Stem cell transplantation in Europe: trends and prospects","volume":"43","author":"Tana","year":"2007","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.jtct.2025.06.004_bib0003","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1200\/JCO.2010.30.2596","article-title":"Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin\u2019s lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry","volume":"29","author":"van Kampen","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2025.06.004_bib0004","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/s41409-019-0516-2","article-title":"et al Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019","volume":"54","author":"Duarte","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.06.004_bib0005","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2025.06.004_bib0006","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2025.06.004_bib0007","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jtct.2025.06.004_bib0008","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2025.06.004_bib0009","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2021-2-4","article-title":"Bispecific antibodies for non- Hodgkin's lymphomas and multiple myeloma","volume":"10","author":"Castaneda-Puglianini","year":"2021","journal-title":"Drugs Context"},{"issue":"4","key":"10.1016\/j.jtct.2025.06.004_bib0010","first-page":"1184","article-title":"Loncastuximab tesirine in relapsed\/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study","volume":"109","author":"Caimi","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2025.06.004_bib0011","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/s41409-024-02248-9","article-title":"Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT","volume":"59","author":"Passweg","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.06.004_bib0012","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jtct.2024.06.025","volume":"30","author":"Madiha Iqbal","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2025.06.004_bib0013","doi-asserted-by":"crossref","first-page":"6157","DOI":"10.1182\/bloodadvances.2020003036","article-title":"CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: an intent-to-treat comparison","volume":"4","author":"Dreger","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2025.06.004_bib0014","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.20.01467","article-title":"Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy","volume":"38","author":"Cappell","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2025.06.004_bib0015","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1002\/cam4.3881","article-title":"Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma","volume":"10","author":"Iacoboni","year":"2021","journal-title":"Cancer Medicine"},{"key":"10.1016\/j.jtct.2025.06.004_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106742","article-title":"Late relapse after CAR-T cell therapy for adult patients with hematologic malignancies: a definite evidence from systematic review and meta-analysis on individual data","volume":"190","author":"Zinzi","year":"2023","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jtct.2025.06.004_bib0017","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2991\/chi.k.210305.001","article-title":"Polatuzumab vedotin: current role and future applications in the treatment of patients with diffuse large B-cell lymphoma","volume":"3","author":"Assi","year":"2021","journal-title":"Clin Hematol Int"},{"key":"10.1016\/j.jtct.2025.06.004_bib0018","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a Novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2025.06.004_bib0019","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jtct.2025.06.004_bib0020","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1182\/blood.2023022348","article-title":"Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed\/refractory B-cell lymphomas","volume":"143","author":"Schuster","year":"2024","journal-title":"Blood"},{"issue":"10466","key":"10.1016\/j.jtct.2025.06.004_bib0021","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(24)01774-4","article-title":"Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial","volume":"404","author":"Abramson","year":"2024","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jtct.2025.06.004_bib0022","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","article-title":"Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research","volume":"15","author":"Giralt","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2025.06.004_bib0023","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1053\/j.seminhematol.2016.01.005","article-title":"Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide","volume":"53","author":"Robinson","year":"2016","journal-title":"Semin Hematol"},{"issue":"5","key":"10.1016\/j.jtct.2025.06.004_bib0024","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1182\/blood-2012-08-453399","article-title":"Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies","volume":"121","author":"Di Bartolomeo","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.06.004_bib0025","doi-asserted-by":"crossref","first-page":"4e10","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.jtct.2025.06.004_bib0026","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.06.004_bib0027","series-title":"The Statistical Analysis of Failure Time Data","author":"Kalbfleisch","year":"1980"},{"key":"10.1016\/j.jtct.2025.06.004_bib0028","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1200\/JCO.2015.63.5904","article-title":"Mantle cell lymphoma","volume":"34","author":"Cheah","year":"2016","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.jtct.2025.06.004_bib0029","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-020-00340-z","article-title":"Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups","volume":"10","author":"Batlevi","year":"2020","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.jtct.2025.06.004_bib0030","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/bjh.18519","article-title":"Real-world experience among patients with relapsed\/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: the SCHOLAR\u22122 retrospective chart review study","volume":"202","author":"Hess","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2025.06.004_bib0031","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/bjh.18197","article-title":"Outcomes of relapsed\/refractory diffuse large B-cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line-a population-based study of 736 patients","volume":"198","author":"Harrysson","year":"2022","journal-title":"Br J Haematol"},{"issue":"13","key":"10.1016\/j.jtct.2025.06.004_bib0032","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1182\/bloodadvances.2024012760","article-title":"Defining primary refractory large B-cell lymphoma","volume":"8","author":"Bock","year":"2024","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.jtct.2025.06.004_bib0033","doi-asserted-by":"crossref","first-page":"159.e1","DOI":"10.1016\/j.jtct.2021.12.013","article-title":"The two-step allogeneic stem cell transplantation approach results in rapid engraftment and excellent outcomes in patients with lymphoid malignancies","volume":"28","author":"Yang","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"10.1016\/j.jtct.2025.06.004_bib0034","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/bjh.19651","article-title":"Reduced-intensity conditioning with fludarabine\/busulfan versus fludarabine\/low-dose melphalan in patients with non-Hodgkin lymphoma undergoing allogeneic haematopoietic stem cell transplantation","volume":"205","author":"Kamijo","year":"2024","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.jtct.2025.06.004_bib0035","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1007\/s00277-024-05677-0","article-title":"Allogeneic stem cell transplantation and CAR-T in B-cell non-Hodgkin Lymphoma: a two-center experience and review of the literature","volume":"103","author":"Mercadal","year":"2024","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.jtct.2025.06.004_bib0036","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.exphem.2013.09.012","article-title":"Outcomes of autologous or allogeneic stem cell transplantation for non-Hodgkin lymphoma","volume":"42","author":"Reddy","year":"2013","journal-title":"Exp Hematol"},{"issue":"7","key":"10.1016\/j.jtct.2025.06.004_bib0037","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.bbmt.2014.03.013","article-title":"Allotransplantation for patients age \u226540 years with non-Hodgkin lymphoma: encouraging progression-free survival","volume":"20","author":"McClune","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.jtct.2025.06.004_bib0038","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.bbmt.2017.03.031","article-title":"Allogeneic stem cell transplantation for relapsed\/refractory B cell lymphomas: results of a multicenter phase II prospective trial including rituximab in the reduced-intensity conditioning regimen","volume":"23","author":"Dodero","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jtct.2025.06.004_bib0039","article-title":"Addition of rituximab in reduced intensity conditioning regimens for B-cell malignancies does not influence transplant outcomes: EBMT registry analyses following allogeneic stem cell transplantation for B-cell malignancies","volume":"2","author":"Tomaszewska","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtct.2025.06.004_bib0040","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00277-011-1395-9","article-title":"Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study","volume":"91","author":"Rigacci","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2025.06.004_bib0041","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1016\/j.bbmt.2015.05.010","article-title":"The impact of graft-versus-host disease on the relapse rate in patients with lymphoma depends on the histological subtype and the intensity of the conditioning regimen","volume":"21","author":"Urbano-Ispizua","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.06.004_bib0042","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/bloodadvances.2018027748","article-title":"PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL","volume":"3","author":"Dreger","year":"2019","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.jtct.2025.06.004_bib0043","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41408-024-01085-9","article-title":"Hematopoietic stem cell transplantation for DLBCL: a report from the European Society for Blood and Marrow Transplantation on more than 40,000 patients over 32 years","volume":"14","author":"Berning","year":"2024","journal-title":"Blood Cancer J"},{"issue":"11","key":"10.1016\/j.jtct.2025.06.004_bib0044","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1038\/sj.leu.2404822","article-title":"Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome","volume":"21","author":"Corradini","year":"2007","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.jtct.2025.06.004_bib0045","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/PPO.0b013e31826b124c","article-title":"Nonmyeloablative allogeneic stem cell transplantation for non-Hodgkin lymphoma","volume":"18","author":"Khouri","year":"2012","journal-title":"Cancer J"},{"issue":"4","key":"10.1016\/j.jtct.2025.06.004_bib0046","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1182\/blood-2017-07-797019","article-title":"Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL network","volume":"131","author":"Aukema","year":"2018","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jtct.2025.06.004_bib0047","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jtct.2021.01.026","article-title":"Cellular therapies for mantle cell lymphoma","volume":"27","author":"Yassine","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2025.06.004_bib0048","doi-asserted-by":"crossref","first-page":"1605e1611","DOI":"10.1016\/j.bbmt.2015.05.007","article-title":"Impact of pretransplantation 18F-fluorodeoxy glucose\u2013positron emission tomography status on outcomes after allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma","volume":"21","author":"Bachanova","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2025.06.004_bib0049","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s11912-023-01403-7","article-title":"allogeneic hematopoietic stem cell transplant for diffuse large B-cell lymphoma: evolving role in the era of CAR T-cell therapy","volume":"25","author":"Hilal","year":"2023","journal-title":"Curr Oncol Rep"},{"issue":"7","key":"10.1016\/j.jtct.2025.06.004_bib0050","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"10343","key":"10.1016\/j.jtct.2025.06.004_bib0051","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.jtct.2025.06.004_bib0052","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2024.19462","article-title":"CAR T cells and T-cell therapies for cancer: a translational science review","volume":"332","author":"Brudno","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.jtct.2025.06.004_bib0053","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1285406","article-title":"Broadening the horizon: potential applications of CAR-T cells beyond current indications","volume":"14","author":"Karsten","year":"2023","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.jtct.2025.06.004_bib0054","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/s41573-023-00807-1","article-title":"Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies","volume":"22","author":"Ruella","year":"2023","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"10.1016\/j.jtct.2025.06.004_bib0055","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.jtct.2025.06.004_bib0056","first-page":"2307","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.06.004_bib0057","series-title":"ASH Annual Meeting","article-title":"Glofitamab monotherapy in relapsed or refractory large b-cell lymphoma: extended follow-up from a pivotal phase II study and subgroup analyses in patients with prior chimeric antigen receptor T-cell therapy and by baseline total metabolic tumor volume","author":"Hutchings","year":"2023"},{"issue":"4","key":"10.1016\/j.jtct.2025.06.004_bib0058","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/j.bbmt.2019.12.771","volume":"26","author":"Dreger","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.jtct.2025.06.004_bib0059","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11912-019-0809-z","article-title":"Is it time to revisit the role of allogeneic transplantation in lymphoma?","volume":"21","author":"Shanbhag","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.jtct.2025.06.004_bib0060","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3324\/haematol.2022.281242","article-title":"Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma","volume":"108","author":"Zurko","year":"2023","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.jtct.2025.06.004_bib0061","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.jtct.2023.09.008","article-title":"Long-term survivors after failure of chimeric antigen receptor T cell therapy for large B cell lymphoma: a role for allogeneic hematopoietic cell transplantation? A German Lymphoma Alliance and German Registry for Stem Cell Transplantation Analysis","volume":"29","author":"Derigs","year":"2023","journal-title":"Transplant Cell Ther"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725012205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725012205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T22:02:35Z","timestamp":1762639355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725012205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":61,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2666636725012205"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.06.004","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-Term Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed\/Refractory B-Cell Non-Hodgkin Lymphoma: An Italian Multicenter Collaborative Study","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}